Sarepta Therapeutics (SRPT) Total Current Liabilities (2010 - 2026)

Sarepta Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $499.2 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 17.57% year-over-year to $499.2 million in Q1 2026; TTM through Mar 2026 was $499.2 million, a 17.57% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 49.69% from the prior year.
• Total Current Liabilities retreated to $499.2 million in Q1 2026 per SRPT's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Total Current Liabilities topped out at $1.1 billion in Q4 2025 and bottomed at $450.7 million in Q3 2023.
• The 5-year median for Total Current Liabilities is $608.7 million (2024), against an average of $654.9 million.
• Across the five-year window, Total Current Liabilities soared 61.45% in 2022 and fell 25.24% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $619.6 million in 2022, then rose by 5.5% to $653.7 million in 2023, then gained by 11.94% to $731.7 million in 2024, then jumped by 49.69% to $1.1 billion in 2025, then slumped by 54.43% to $499.2 million in 2026.
• Per Business Quant, the three latest SRPT Total Current Liabilities figures stand at $499.2 million (Q1 2026), $1.1 billion (Q4 2025), and $921.4 million (Q3 2025).